This week in drug discovery (2-6 June)
News round-up for 2-6 June by DDW Senior Digital Content Editor Diana Spencer.
With conference season in full swing and the speakers announced for DDW’s Turning Science into Business Symposium in November, our news round-up shines a light on the importance of these in-person events for sharing and discovering the latest drug discovery breakthroughs.
The top stories:
Tessera Therapeutics presents new clinical data
Biotech Tessera Therapeutics has presented updates across its in vivo genetic medicine programmes for Alpha-1 antitrypsin deficiency (AATD), Phenylketonuria (PKU), and Sickle Cell Disease (SCD), as well as advances in in vivo T cell therapies.
Sentinel BioTherapeutics launches at 2025 ASCO Annual Meeting
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting.
Cerno unveils mass spec breakthroughs at ASMS Meeting
Cerno will present new data on its universal mass spectrometry software at the American Society of Mass Spectrometry (ASMS) Annual Meeting in Baltimore MD.
BIAL to present at GBA1 Meeting 2025 on Parkinson’s treatment
BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada.
Perspective shares positive responses in NETs at ASCO
Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.